These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2352 related articles for article (PubMed ID: 34449189)

  • 1. Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    Anker SD; Butler J; Filippatos G; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure-Valenzuela E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Carson P; Lam CSP; Marx N; Zeller C; Sattar N; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    N Engl J Med; 2021 Oct; 385(16):1451-1461. PubMed ID: 34449189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
    Packer M; Anker SD; Butler J; Filippatos G; Pocock SJ; Carson P; Januzzi J; Verma S; Tsutsui H; Brueckmann M; Jamal W; Kimura K; Schnee J; Zeller C; Cotton D; Bocchi E; Böhm M; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Janssens S; Zhang J; Gonzalez Juanatey JR; Kaul S; Brunner-La Rocca HP; Merkely B; Nicholls SJ; Perrone S; Pina I; Ponikowski P; Sattar N; Senni M; Seronde MF; Spinar J; Squire I; Taddei S; Wanner C; Zannad F;
    N Engl J Med; 2020 Oct; 383(15):1413-1424. PubMed ID: 32865377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
    Filippatos G; Butler J; Farmakis D; Zannad F; Ofstad AP; Ferreira JP; Green JB; Rosenstock J; Schnaidt S; Brueckmann M; Pocock SJ; Packer M; Anker SD;
    Circulation; 2022 Aug; 146(9):676-686. PubMed ID: 35762322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
    Packer M; Butler J; Zannad F; Filippatos G; Ferreira JP; Pocock SJ; Carson P; Anand I; Doehner W; Haass M; Komajda M; Miller A; Pehrson S; Teerlink JR; Schnaidt S; Zeller C; Schnee JM; Anker SD
    Circulation; 2021 Oct; 144(16):1284-1294. PubMed ID: 34459213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
    Abraham WT; Ponikowski P; Brueckmann M; Zeller C; Macesic H; Peil B; Brun M; Ustyugova A; Jamal W; Salsali A; Lindenfeld J; Anker SD;
    Eur J Heart Fail; 2019 Jul; 21(7):932-942. PubMed ID: 31218819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
    J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
    Ferreira JP; Zannad F; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Jamal W; Steubl D; Schueler E; Packer M
    J Am Coll Cardiol; 2021 Mar; 77(11):1397-1407. PubMed ID: 33736821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    McMurray JJV; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Anand IS; Bělohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett JG; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Petrie MC; Vinh PN; Schou M; Tereshchenko S; Verma S; Held C; DeMets DL; Docherty KF; Jhund PS; Bengtsson O; Sjöstrand M; Langkilde AM;
    N Engl J Med; 2019 Nov; 381(21):1995-2008. PubMed ID: 31535829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin after Acute Myocardial Infarction.
    Butler J; Jones WS; Udell JA; Anker SD; Petrie MC; Harrington J; Mattheus M; Zwiener I; Amir O; Bahit MC; Bauersachs J; Bayes-Genis A; Chen Y; Chopra VK; Figtree G; Ge J; Goodman SG; Gotcheva N; Goto S; Gasior T; Jamal W; Januzzi JL; Jeong MH; Lopatin Y; Lopes RD; Merkely B; Parikh PB; Parkhomenko A; Ponikowski P; Rossello X; Schou M; Simic D; Steg PG; Szachniewicz J; van der Meer P; Vinereanu D; Zieroth S; Brueckmann M; Sumin M; Bhatt DL; Hernandez AF
    N Engl J Med; 2024 Apr; 390(16):1455-1466. PubMed ID: 38587237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
    Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Malik ME; Fosbøl EL; Bruun NE; Forman JL; Jensen LT; Møller JE; Schou M
    Lancet Diabetes Endocrinol; 2021 Feb; 9(2):106-116. PubMed ID: 33357505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Carson P; Anand I; Doehner W; Haass M; Komajda M; Miller A; Pehrson S; Teerlink JR; Brueckmann M; Jamal W; Zeller C; Schnaidt S; Zannad F
    Circulation; 2021 Jan; 143(4):326-336. PubMed ID: 33081531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
    Verma S; Dhingra NK; Butler J; Anker SD; Ferreira JP; Filippatos G; Januzzi JL; Lam CSP; Sattar N; Peil B; Nordaby M; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Lancet Diabetes Endocrinol; 2022 Jan; 10(1):35-45. PubMed ID: 34861154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Claggett B; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Jhund PS; Belohlavek J; Chiang CE; Borleffs CJW; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer-Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Saraiva JFK; Tereshchenko SN; Thierer J; Vaduganathan M; Vardeny O; Verma S; Pham VN; Wilderäng U; Zaozerska N; Bachus E; Lindholm D; Petersson M; Langkilde AM;
    N Engl J Med; 2022 Sep; 387(12):1089-1098. PubMed ID: 36027570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
    Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Fosbøl EL; Bruun NE; Brønd JC; Forman JL; Videbæk L; Møller JE; Schou M
    Am Heart J; 2020 Oct; 228():47-56. PubMed ID: 32798787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B; Wanner C; Lachin JM; Fitchett D; Bluhmki E; Hantel S; Mattheus M; Devins T; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE;
    N Engl J Med; 2015 Nov; 373(22):2117-28. PubMed ID: 26378978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
    Anker SD; Butler J; Filippatos G; Khan MS; Marx N; Lam CSP; Schnaidt S; Ofstad AP; Brueckmann M; Jamal W; Bocchi EA; Ponikowski P; Perrone SV; Januzzi JL; Verma S; Böhm M; Ferreira JP; Pocock SJ; Zannad F; Packer M
    Circulation; 2021 Jan; 143(4):337-349. PubMed ID: 33175585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis.
    Ferreira JP; Zannad F; Packer M; Filippatos G; Pocock SJ; Vasques-Nóvoa F; Böhm M; Butler J; Anker S
    Eur J Heart Fail; 2024 Apr; 26(4):952-959. PubMed ID: 38439585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 118.